

# Pascal Bus

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2314571/publications.pdf>

Version: 2024-02-01

6  
papers

126  
citations

1478505

6  
h-index

1872680

6  
g-index

6  
all docs

6  
docs citations

6  
times ranked

173  
citing authors

#	ARTICLE	IF	CITATIONS
1	The VEGF-A inhibitor sFLT-1 improves renal function by reducing endothelial activation and inflammation in a mouse model of type 1 diabetes. <i>Diabetologia</i> , 2017, 60, 1813-1821.	6.3	37
2	Complement Activation in Patients With Diabetic Nephropathy. <i>Kidney International Reports</i> , 2018, 3, 302-313.	0.8	37
3	Apolipoprotein Câ€ plays a role in the pathogenesis of glomerulosclerosis. <i>Journal of Pathology</i> , 2017, 241, 589-599.	4.5	24
4	Endoglin Mediates Vascular Endothelial Growth Factor-Induced Endothelial Cell Activation by Regulating Akt Signaling. <i>American Journal of Pathology</i> , 2018, 188, 2924-2935.	3.8	11
5	Glomerular clusterin expression is increased in diabetic nephropathy and protects against oxidative stress-induced apoptosis in podocytes. <i>Scientific Reports</i> , 2020, 10, 14888.	3.3	9
6	The Vascular Endothelial Growth Factor Inhibitor Soluble FLT-1 Ameliorates Atopic Dermatitis in APOC1 Transgenic Mice. <i>Journal of Investigative Dermatology</i> , 2020, 140, 491-494.e4.	0.7	8